ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arcturus Therapeutics Holdings Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.42+0.08 (+0.77%)
Close on Oct 19, 2026
- Market cap
- $296.17M
- P/E (TTM)
- –
- Dividend yield
- –
Arcturus Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Arcturus Therapeutics | Industry median |
|---|---|---|
| Market Cap | $296.17M | $164.85M |
| Enterprise Value | $104.69M | $87.06M |
| PS Ratio | 10.09 | 3.60 |
| PB Ratio | 1.72 | 2.03 |
| P/TBV Ratio | 1.72 | 2.31 |
Enterprise value
| Measure | Arcturus Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 3.56 | 2.43 |
Income (trailing twelve months)
| Measure | Arcturus Therapeutics | Industry median |
|---|---|---|
| Revenue | $29.37M | $57.94M |
| Operating Income | -$102.30M | -$21.44M |
| Net Income | -$93.28M | -$22.46M |
| EBITDA | -$99.56M | -$16.91M |
| EPS (Diluted) | -$3.31 | -$0.83 |
Margins
| Measure | Arcturus Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -348.3% | -44.5% |
| Profit Margin | -317.6% | -39.2% |
| EBITDA Margin | -339.0% | -31.3% |
| FCF Margin | -248.0% | -8.85% |
Returns
| Measure | Arcturus Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -46.3% | -53.1% |
| Return on Assets (ROA) | -35.0% | -41.0% |
| Return on Invested Capital (ROIC) | -1083.9% | -32.0% |
| Return on Capital Employed (ROCE) | -53.6% | -37.8% |
Growth
| Measure | Arcturus Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -76.0% | 6.01% |
| Revenue Growth (3Y CAGR) | -26.4% | 2.25% |
| Revenue Growth (5Y CAGR) | 53.8% | 6.42% |
Balance sheet
| Measure | Arcturus Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $191.48M | $62.42M |
| Net Cash (Debt) | $191.48M | $15.68M |
| Net Cash Per Share | $6.74 | $0.66 |
| Equity (Book Value) | $171.81M | $48.79M |
| Book Value Per Share | $6.04 | $1.36 |
| Tangible Book Value | $171.81M | $23.06M |
| Working Capital | $163.63M | $75.77M |
Financial position
| Measure | Arcturus Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 5.88 | 3.30 |
| Quick Ratio | 5.76 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Arcturus Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$72.73M | -$12.35M |
| Capital Expenditures | -$93.00K | -$1.06M |
| Free Cash Flow | -$72.82M | -$20.28M |
| FCF Per Share | -$2.56 | -$0.42 |
Efficiency
| Measure | Arcturus Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.11 | 0.38 |
| Revenue Per Employee | $264.57K | $398.96K |
| Profits Per Employee | -$840.32K | -$703.34K |
| Employee Count | 111 | 74 |
Dividends and yields
| Measure | Arcturus Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -31.5% | -22.7% |
| FCF Yield | -24.6% | -9.07% |
Shares
| Measure | Arcturus Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 28,423,100 | 58,179,650 |
| Shares Change (YoY) | 3.47% | 11.1% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 26,134,400 | 49,173,100 |
| Shares Held by Insiders | 8.05% | 11.6% |
| Shares Held by Institutions | 87.9% | 59.4% |
Scores
| Measure | Arcturus Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -0.64 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Arcturus Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.